Fig. 2.

Tunicamycin inhibits proliferation of ER^–/PR^–/HER2^– (triple negative; MDA-MB-231) and estrogen receptor positive (MCF-7) breast cancer cells. Triple negative human breast cancer cells (MDA-MB-231) were seeded (2 × 10⁴ cells/well) in 24-well plates, synchronized in serum-free media for 24 h and treated with tunicamycin (0, 0.1, 1.0 and 10.0 μg/mL) in a 2% serum-containing media for 7 days. The cells were counted after every 24 h in a haemocytometer. Estrogen receptor positive human breast cancer cells (MCF-7) were seeded (2 × 10⁴ cells/well) in 24-well plates, synchronized in serum-free media for 48 h and treated with tunicamycin (0, 0.1, 1.0 and 10.0 μg/mL) in a 2% serum-containing media for 24 h. The cells were counted in a haemocytometer. The error bars represent the standard deviations (mean ± SD) for n = 3.